PULM Stock Summary and Trading Ideas (Pulmatrix | NASDAQ:PULM)

Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

Pulmatrix trades on the NASDAQ stock market under the symbol PULM.

As of June 9, 2026, PULM stock price declined to $1.38 with 46,249 million shares trading.

PULM has a beta of 1.64, meaning it tends to be more sensitive to market movements. PULM has a correlation of 0.04 to the broad based SPY ETF.

PULM has a market cap of $5.04 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, PULM traded as high as $10.40 and as low as $1.16.

The top ETF exchange traded funds that PULM belongs to (by Net Assets): VXF, VTI.

PULM has underperformed the market in the last year with a return of -84.5%, while the SPY ETF gained +24.3%. In the last 3 month period, PULM fell short of the market, returning -31.7%, while SPY returned +9.9%. However, in the most recent 2 weeks PULM has outperformed the stock market by returning +3.0%, while SPY returned -1.2%.

PULM support price is $1.34 and resistance is $1.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PULM shares will trade within this expected range on the day.